GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Biopharmaceuticals Co Ltd (XKRX:326030) » Definitions » EV-to-FCF

SK Biopharmaceuticals Co (XKRX:326030) EV-to-FCF : -71.36 (As of May. 17, 2024)


View and export this data going back to 2020. Start your Free Trial

What is SK Biopharmaceuticals Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SK Biopharmaceuticals Co's Enterprise Value is ₩6,953,799 Mil. SK Biopharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-97,451 Mil. Therefore, SK Biopharmaceuticals Co's EV-to-FCF for today is -71.36.

The historical rank and industry rank for SK Biopharmaceuticals Co's EV-to-FCF or its related term are showing as below:

XKRX:326030' s EV-to-FCF Range Over the Past 10 Years
Min: -205.47   Med: -48.99   Max: -20.87
Current: -71.36

During the past 13 years, the highest EV-to-FCF of SK Biopharmaceuticals Co was -20.87. The lowest was -205.47. And the median was -48.99.

XKRX:326030's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 7.68 vs XKRX:326030: -71.36

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), SK Biopharmaceuticals Co's stock price is ₩89600.00. SK Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-420.000. Therefore, SK Biopharmaceuticals Co's PE Ratio for today is At Loss.


SK Biopharmaceuticals Co EV-to-FCF Historical Data

The historical data trend for SK Biopharmaceuticals Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Biopharmaceuticals Co EV-to-FCF Chart

SK Biopharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -57.16 -73.77 -33.14 -80.42

SK Biopharmaceuticals Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.14 -30.82 -42.77 -53.76 -80.42

Competitive Comparison of SK Biopharmaceuticals Co's EV-to-FCF

For the Biotechnology subindustry, SK Biopharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SK Biopharmaceuticals Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SK Biopharmaceuticals Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where SK Biopharmaceuticals Co's EV-to-FCF falls into.



SK Biopharmaceuticals Co EV-to-FCF Calculation

SK Biopharmaceuticals Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6953798.814/-97450.613
=-71.36

SK Biopharmaceuticals Co's current Enterprise Value is ₩6,953,799 Mil.
SK Biopharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-97,451 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SK Biopharmaceuticals Co  (XKRX:326030) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SK Biopharmaceuticals Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=89600.00/-420.000
=At Loss

SK Biopharmaceuticals Co's share price for today is ₩89600.00.
SK Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-420.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


SK Biopharmaceuticals Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of SK Biopharmaceuticals Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SK Biopharmaceuticals Co (XKRX:326030) Business Description

Traded in Other Exchanges
N/A
Address
221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.

SK Biopharmaceuticals Co (XKRX:326030) Headlines

No Headlines